Literature DB >> 9739387

[Retardation of progression of bone metastasis in mammary carcinoma patients by intravenous pamidronate treatment: results of a randomized, controlled, multinational study].

I A Adamietz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9739387     DOI： 10.1007/bf03038568

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  3 in total

1.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

Authors:  G N Hortobagyi; R L Theriault; L Porter; D Blayney; A Lipton; C Sinoff; H Wheeler; J F Simeone; J Seaman; R D Knight
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

2.  Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

Authors:  P F Conte; J Latreille; L Mauriac; F Calabresi; R Santos; D Campos; J Bonneterre; G Francini; J M Ford
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

3.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

Authors:  J R Berenson; A Lichtenstein; L Porter; M A Dimopoulos; R Bordoni; S George; A Lipton; A Keller; O Ballester; M J Kovacs; H A Blacklock; R Bell; J Simeone; D J Reitsma; M Heffernan; J Seaman; R D Knight
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245
  3 in total
  1 in total

Review 1.  Osteonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies.

Authors:  Vassilios Vassiliou; Nikolaos Tselis; Dimitrios Kardamakis
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.